ELA (European Leukodystrophy Association) has funded a phase 2/3 clinical trial with MD1003 in adults for X-linked adrenoleukodystrophy. The company is developing relationships with other international patient associations.

MedDay SA au capital de 116 660 €
Siège social : 96 Boulevard Haussmann 75008 Paris
RCS PARIS 534 957 865
Publication Director : Dr Frédéric Sedel